Free Trial

Arcus Biosciences (NYSE:RCUS) Stock Price Down 5.8% - Should You Sell?

Arcus Biosciences logo with Medical background
Remove Ads

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report)'s stock price traded down 5.8% on Tuesday . The stock traded as low as $9.95 and last traded at $9.90. 387,331 shares changed hands during mid-day trading, a decline of 45% from the average session volume of 708,444 shares. The stock had previously closed at $10.50.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Bank of America lowered their price target on Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating on the stock in a report on Wednesday, February 19th. HC Wainwright raised Arcus Biosciences from a "neutral" rating to a "buy" rating and raised their price target for the company from $18.00 to $24.00 in a report on Wednesday, February 26th. Finally, Morgan Stanley reduced their price objective on Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 18th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $30.25.

Check Out Our Latest Stock Report on RCUS

Arcus Biosciences Price Performance

The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. The stock has a market capitalization of $1.01 billion, a P/E ratio of -3.04 and a beta of 1.36. The firm has a 50-day moving average price of $12.90 and a 200 day moving average price of $15.25.

Remove Ads

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.17) by $0.14. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The business had revenue of $36.00 million for the quarter, compared to analyst estimates of $29.38 million. On average, analysts expect that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Insider Buying and Selling

In related news, CFO Robert C. Goeltz II sold 3,594 shares of the firm's stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total transaction of $53,910.00. Following the transaction, the chief financial officer now directly owns 60,138 shares in the company, valued at $902,070. This trade represents a 5.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Yasunori Kaneko acquired 20,000 shares of the company's stock in a transaction on Thursday, February 27th. The stock was acquired at an average price of $10.06 per share, with a total value of $201,200.00. Following the acquisition, the director now owns 28,400 shares in the company, valued at approximately $285,704. This trade represents a 238.10 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Arcus Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. R Squared Ltd purchased a new stake in Arcus Biosciences in the 4th quarter worth approximately $26,000. Point72 Hong Kong Ltd purchased a new stake in Arcus Biosciences in the 3rd quarter worth approximately $47,000. Lazard Asset Management LLC lifted its holdings in Arcus Biosciences by 3,321.3% in the 4th quarter. Lazard Asset Management LLC now owns 6,261 shares of the company's stock worth $93,000 after buying an additional 6,078 shares during the period. US Bancorp DE lifted its holdings in Arcus Biosciences by 2,432.0% in the 4th quarter. US Bancorp DE now owns 6,887 shares of the company's stock worth $103,000 after buying an additional 6,615 shares during the period. Finally, Quest Partners LLC lifted its holdings in Arcus Biosciences by 40,904.3% in the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company's stock worth $144,000 after buying an additional 9,408 shares during the period. Hedge funds and other institutional investors own 92.89% of the company's stock.

Arcus Biosciences Company Profile

(Get Free Report)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

Featured Stories

Should You Invest $1,000 in Arcus Biosciences Right Now?

Before you consider Arcus Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.

While Arcus Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads